Valuation: BriaCell Therapeutics Corp.

Market Cap 2.99Cr 2.56Cr 2.4Cr 2.19Cr 4.13Cr 286.21Cr 4.18Cr 28Cr 11Cr 143.72Cr 11Cr 11Cr 475.51Cr P/E 2024
-2.56x
P/E 2025 -0.12x
Enterprise Value 1.2Cr 1.03Cr 96.4L 88.14L 1.66Cr 115.14Cr 1.68Cr 11Cr 4.44Cr 58Cr 4.51Cr 4.42Cr 191.29Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.49%
Yield 2024 *
-
Yield 2025 -
1 day-13.31%
1 week+2.55%
1 month-4.17%
3 months+0.63%
6 months-3.98%
Current year-50.82%
1 week 4.78
Extreme 4.78
5.75
1 month 4.61
Extreme 4.61
5.75
Current year 3.68
Extreme 3.68
16.5
1 year 3.68
Extreme 3.68
20.4
3 years 3.68
Extreme 3.68
1,543.5
5 years 3.68
Extreme 3.68
2,362.5
10 years 3.68
Extreme 3.68
11,250.11
Manager TitleAgeSince
Chief Executive Officer 70 01/11/2016
Director of Finance/CFO 54 01/02/2016
Chief Tech/Sci/R&D Officer 65 16/02/2022
Director TitleAgeSince
Director/Board Member 70 01/11/2016
Chairman 41 24/04/2019
Director/Board Member 74 07/03/2019
Date Insider Type Main position Quantity % Market Cap.
07/07/26 Tax

Director

45,000 0.5173%
07/07/26 Tax

Director

15,000 0.1724%
07/07/26 Option

Chief Financial Officer

28,257 0.3248%
Change 5-day change 1-year change 3-year change Capi.($)
-13.31%+2.55%-49.26%-99.68% 3.03Cr
-4.31%-6.62%+65.79%+98.02% 6.91TCr
+1.02%+0.32%+47.93%+86.02% 6.31TCr
-3.22%+23.17%+1.75%-5.23% 2.83TCr
-1.42%-3.38%-5.99%+465.34% 2.71TCr
+7.41%+7.45%+56.85%+17.70% 2.55TCr
+2.25%+2.52%+37.00%-16.17% 1.97TCr
+5.36%+4.61%+270.18%+415.10% 1.92TCr
+0.10%-3.50%+11.43%+519.16% 1.6TCr
+0.87%+4.26%+41.21%+150.80% 1.35TCr
Average -0.40%+3.20%+47.69%+163.11% 2.81TCr
Weighted average by Cap. +0.06%+1.66%+55.27%+153.04%

Financials

2024 2025
Net sales - -
Net income -47.91L -41.06L -38.41L -35.12L -66.28L -46Cr -66.98L -4.55Cr -1.77Cr -23Cr -1.8Cr -1.76Cr -76Cr -2.63Cr -2.25Cr -2.11Cr -1.93Cr -3.64Cr -251.94Cr -3.68Cr -25Cr -9.71Cr -126.51Cr -9.88Cr -9.67Cr -418.58Cr
Net Debt -9L -7L -7L -6L -11.92L -8.25Cr -12.05L -81.79L -31.8L -4.15Cr -32.37L -31.67L -14Cr -1.79Cr -1.53Cr -1.43Cr -1.31Cr -2.47Cr -171.07Cr -2.5Cr -17Cr -6.59Cr -86Cr -6.71Cr -6.56Cr -284.22Cr
Logo BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Employees
16
Date Price Change Volume
24/26/24 CA$4.820 -13.31% 25,391
21/26/21 CA$5.560 +1.46% 9,309
20/26/20 CA$5.480 +0.55% 7,371
19/26/19 CA$5.450 +12.37% 8,027
18/26/18 CA$4.850 +3.19% 6,800

Quarterly revenue - Rate of surprise